Seeking Alpha
 

Oncothyreon Inc . (ONTY)

- NASDAQ
  • Dec. 19, 2012, 8:39 AM
    Stimuvax, a lung cancer vaccine that Germany's Merck (MKGAF.PK) has licensed from Oncothyreon (ONTY), failed to improve overall survival in a Phase III study. However, "notable treatment effects were observed in certain subgroups of patients." That's not enough to convince analysts: "Despite potential positive effects in subgroups, we consider the drug dead," says Deutsche Bank. Oncothyreon collapses 61%, while Merck is -2.9% in Frankfurt. (PR)
    | Dec. 19, 2012, 8:39 AM | Comment!
  • Nov. 7, 2012, 4:53 PM
    Oncothyreon (ONTY): Q3 EPS of -$0.15 in-line. (PR)
    | Nov. 7, 2012, 4:53 PM | Comment!
  • Nov. 7, 2012, 12:10 AM
    Notable earnings after Wednesday’s close: ARAY, ATO, ATVI, AWK, BONE, CBS, CLR, CODI, CPE, CPNO, CTL, CXO, ETE, ETP, EXEL, FTK, GMXR, GSS, HIMX, HNSN, ITMN, KGC, MAKO, MBI, MDLZ, MNST, MWE, NQ, OAS, ONTY, OSUR, PAAS, PANL, PRI, PRU, QCOM, SGEN, SLXP, SNTS, SRZ, SSRI, SXL, TCAP, TIE, TS, WFM
    | Nov. 7, 2012, 12:10 AM | Comment!
  • Nov. 6, 2012, 5:35 PM
    Notable earnings after Wednesday’s close: ARAY, ATO, ATVI, AWK, BONE, CBS, CLR, CODI, CPE, CPNO, CTL, CXO, ETE, ETP, EXEL, FTK, GMXR, GSS, HIMX, HNSN, ITMN, KGC, MAKO, MBI, MDLZ, MNST, MWE, NQ, OAS, ONTY, OSUR, PAAS, PANL, PRI, PRU, QCOM, SGEN, SLXP, SNTS, SRZ, SSRI, SXL, TCAP, TIE, TS, WFM
    | Nov. 6, 2012, 5:35 PM | Comment!
  • Aug. 24, 2012, 10:38 AM
    Oncothyreon (ONTY +10.8%) pops after Stifel Nicolaus initiated coverage this morning with a Buy. Not much detail is given, but a couple of catalysts are worth noting. First, its lead product candidate, Stimuvax, is a cancer vaccine in the latter stages of being evaluated in two Phase 3 clinical trials for the treatment of non-small cell lung cancer, with the results due out in early 2013. Second, the shares have lost nearly half their market value since early March, and with the stock currently trading off its 50-day moving average as support, it could be spring-loaded for an upside surprise.
    | Aug. 24, 2012, 10:38 AM | Comment!
  • Aug. 24, 2012, 9:10 AM
    Premarket gainers: ARUN +14%. MTSL +12%. CPRX +10%. LLY +8%. DSCO +7%. FRO +5%. ONTY +5%.
    Losers: ADSK -22%. HMSY -5%.
    | Aug. 24, 2012, 9:10 AM | Comment!
  • Aug. 8, 2012, 12:10 AM
    Notable earnings after Wednesday’s close: ATPG, AUY, AVNR, CJES, CLR, CPE, CPNO, CTL, EGLE, EXXI, FTK, GMXR, GSS, GXP, HNSN, HOGS, KGC, MBI, MDRX, MM, MNST, NQ, NWSA, ONTY, PANL, SATC, SCLN, SGEN, SPWR, TEG, ZGNX
    | Aug. 8, 2012, 12:10 AM | Comment!
  • Aug. 7, 2012, 5:35 PM
    Notable earnings after Wednesday’s close: ATPG, AUY, AVNR, CJES, CLR, CPE, CPNO, CTL, EGLE, EXXI, FTK, GMXR, GSS, GXP, HNSN, HOGS, KGC, MBI, MDRX, MM, MNST, NQ, NWSA, ONTY, PANL, SATC, SCLN, SGEN, SPWR, TEG, ZGNX
    | Aug. 7, 2012, 5:35 PM | 2 Comments
  • May 7, 2012, 5:03 PM
    Oncothyreon (ONTY): Q1 EPS of $0.21 may not be comparable to consensus of by -$0.17. Shares -0.9% AH. (PR)
    | May 7, 2012, 5:03 PM | 1 Comment
  • Mar. 29, 2012, 9:15 AM
    Premarket gainers: PSS +11%. RHT +7%. THLS +6%. ILMN +4%. ZLCS +3%. HERO +3%. BNNY +3%.
    Losers: CHTP -29%. NBG -6%. NCT -5%. JBLU -4%. BBY -4%. ATPG -3%. ONTY -3%. MTL -3%. ING -3%. BCS -3%. VVUS -3%. ARNA -3%. TOT -3%.
    | Mar. 29, 2012, 9:15 AM | Comment!
  • Mar. 28, 2012, 4:40 PM
    Oncothyreon (ONTY) -5.1% AH after announcing a stock offering of undisclosed size. The company plans to use the proceeds to fund the development of its PX-866 cancer drug, as well as its ONT-10 vaccine. (PR)
    | Mar. 28, 2012, 4:40 PM | Comment!
  • Mar. 6, 2012, 9:05 AM
    Premarket gainers: VRML +14%. HNR +12%. CYTK +10%. NBG +8%. MWW +7%.
    Losers: ONTY -40%. ZLTQ -14%. AEZS -12%. NTRI -11%. KERX -8%. RAS -6%. VVUS -6%. CNX -5%.
    | Mar. 6, 2012, 9:05 AM | Comment!
  • Mar. 6, 2012, 6:52 AM
    Shares of Oncothyreon (ONTY) fall 32.4% in premarket trading after Merck KgaA (MKGAF.PK) announces that studies on the experimental lung-cancer drug Stimuvax won't be completed until next year. Stimuvax is being developed by Merck KGaA under a license agreement with Oncothyreon.
    | Mar. 6, 2012, 6:52 AM | Comment!
  • Jan. 24, 2012, 8:57 AM
    Shares of Oncothyreon (ONTY) get a lift from a price target increase from JMP Securities. Analyst with the firm raise their PT to $14 from $8 - marking 125% upside potential. Shares +3.7% premarket.
    | Jan. 24, 2012, 8:57 AM | 1 Comment
  • Dec. 23, 2011, 9:56 AM
    Oncothyreon (ONTY -2.1%) trades lower after the firm files (S-3) a shelf registration with the SEC to sell up to $150M in securities including common stock, preferred shares, debt issues, and warrants.
    | Dec. 23, 2011, 9:56 AM | Comment!
  • Dec. 20, 2011, 11:43 AM
    Oncothyreon (ONTY +2.1%) announces the filing of an Investigational New Drug application with the FDA for ONT-10, a therapeutic vaccine directed at cancers expressing MUC1. Upon completion of the review, expects to initiate a Phase 1 trials.
    | Dec. 20, 2011, 11:43 AM | Comment!
Visit Seeking Alpha's
ONTY vs. ETF Alternatives
Company Description
Oncothyreon Inc is a clinical-stage biopharmaceutical company. It develops and commercialize synthetic vaccines & small molecules that treat the lives & outcomes of cancer patients.
Sector: Healthcare
Industry: Biotechnology
Country: United States